The answer depends on the drug. In a 43-person study, injectable semaglutide did not lower exposure to the specific combined pill tested [1]. The prescribing information for tirzepatide and Foundayo gives separate instructions for people who use oral hormonal contraception [7] [8] [9].
If you are planning a pregnancy, the guide to stopping a GLP-1 before conception explains how timing differs by product. Discuss when to stop with the clinician who manages your treatment.
That study enrolled postmenopausal women with type 2 diabetes. It measured drug exposure. The results cannot establish how often pregnancies occur in people taking both medicines.
The Danish registry analysis examined prior contraceptive prescriptions and later semaglutide initiation among 249,634 participants. The adjusted hazard ratio was 1.42 for combined oral tablets and reached 2.11 in one category involving multiple contraceptive types [6]. The study did not measure contraceptive effectiveness during GLP-1 treatment.
What tirzepatide and Foundayo labels advise
The Zepbound and Mounjaro labels advise switching to a non-oral contraceptive or adding a barrier method for four weeks after starting tirzepatide and four weeks after each dose increase [7] [8]. The Foundayo guide covers the oral medicine separately. Its label gives a 30-day interval after starting and after each increase, and says its effect on pill absorption has not been tested in a trial[9].
Oral contraception: what the semaglutide study measured
The specific question has been tested. Forty-three postmenopausal women with type 2 diabetes took a combined oral contraceptive daily for eight days. That ran before and during semaglutide treatment at a 1.0 mg steady state[1]. The pill was ethinylestradiol 0.03 mg with levonorgestrel 0.15 mg, and the usual dose escalation came first.
The bioequivalence criterion was met for ethinylestradiol exposure, with a ratio of 1.11 (90% CI 1.06 to 1.15) against the prespecified 0.80 to 1.25 limits. Levonorgestrel exposure was 20% higher at semaglutide steady state, a ratio of 1.20 (90% CI 1.15 to 1.26). Peak concentration for both sat inside the bioequivalence range[1]. The conclusion the paper draws is the one in its title: semaglutide does not reduce the bioavailability of that combined oral contraceptive.
The broader interaction question has been reviewed systematically. A review covered 22 reports and six prescribing sheets on injectable GLP-1 receptor agonists given with oral medications[2]. Treatment left peak concentration unaffected or reduced it, and delayed the time to peak. That held across drugs of differing solubility and permeability, contraceptive pills among them. The review found few clinically significant changes among the studies it included [2]. A later review identified changes in oral contraceptive exposure with tirzepatide[3].
Delayed stomach emptying can change how quickly some oral drugs reach the bloodstream. Ask your prescriber about any medicines that require close monitoring [2]. For oral contraceptives, check the instructions for your specific GLP-1 product.
What testosterone studies tell us about sexual function
A meta-analysis pooled seven studies with 680 men and found an increase in total testosterone after treatment [4]. Results varied across studies. The analysis could not isolate a direct drug effect from changes associated with weight loss.
The evidence on erectile function is mixed [5]. A change in testosterone alone cannot establish a change in erections or sexual desire. The studies cited here also do not establish how GLP-1 treatment affects sexual function in women.
A study of one combined pill cannot establish how all contraceptives perform with every GLP-1 drug. The labels for tirzepatide and Foundayo give specific instructions for people who take oral contraceptives. Discuss your medication and contraceptive method with your prescriber.